The strongest of the novel hits from this analysis implicates a SNP in the region between BCL10 and DDAH1 [119]; BCL10 is an activator of nuclear factor (NF)-κB signaling which is involved in gene expression control of inflammation, immunity, cell proliferation and apoptosis and has been explored as a clinical target for MS [73,119,121]. Here, BCL10 is linked to myeloid sarcoma.